-
From 2005 to 2020, a total of 16.2 million PTB cases were reported, with an average reported incidence of 75.5 per 100,000 population, and the notified incidence declined by 55% from 2005 (1.4 million cases, 108.3 per 100,000 population) to 2020 (0.7 million cases, 49.2 per 100,000 population). The average ASR is per 100,000 individuals. The ASR was the highest in 2005 (116.9 per 100,000 population) and the lowest in 2020 (47.6 per 100,000 population), with a slower rate of decline after 2011 (Figure 2A).
Figure 2. Changes in the notified incidence of PTB rate in China. (A) overall; (B) female vs. male; (C) 4 age groups: (D) urban vs. rural; (E) 7 geographic areas.
Joinpoint regression analysis showed that the reported incidence rate of TB in China decreased by 5.6% annually from 2005 to 2020 (APC = −5.6, 95% CI: −7.0 to −4.2), showing different trends in four periods. The largest changes occurred in 2018. (Table 1 and Supplementary Figure S1, available in www.besjournal.com). Segment analysis showed a 5.1% decline from 2005 to 2008 (APC = −5.1, 95% CI: −7.9 to −2.2), a larger decline occurred in 2008–2011 (APC = −8.6, 95% CI: −14.5 to −2.4), the smallest decline occurred in 2011–2018 (APC = −3.4, 95% CI: −4.6 to −2.3), and the largest decline occurred in 2018–2020 (APC = −9.2, 95% CI: −16.4 to −1.3).
Table 1. Joinpoint regression analysis results of notified incidence of PTB in China
Characteristics Year Notification rates of PTB cases# Annual percent change (95% CI) AAPC (95% CI) Overall 2005–2008 108.3–94.6 −5.1* (−7.9, −2.2) −5.6* (−7.0, −4.2) 2008–2011 94.6–75.6 −8.6* (−14.5, −2.4) 2011–2018 75.6–61.6 −3.4* (−4.6, −2.3) 2018–2020 61.6–49.2 −9.2* (−16.4, −1.3) Sex Female 2005–2011 67.7–46.7 −6.5* (−7.8, −5.3) −4.9* (−5.5, −4.2) 2011–2020 46.7–31.8 −3.7* (−4.6, −2.9) Male 2005–2013 146.6–93.9 −6.7* (−7.5, −5.9) −6.0* (−7.3, −4.7) 2013–2018 93.9–82.9 −3.0* (−5.5, −0.3) 2018–2020 82.9–65.9 −10.6* (−18.8, −1.5) Age group 0–14 2005–2010 10.8–3.9 −17.4* (−18.6, −16.1) −7.3* (−8.6, −6.0) 2010–2014 3.9–3.0 −9.1* (−13.8, −4.0) 2014–2020 3.0–3.5 3.3* (1.4, 5.2) 15–34 2005–2015 101.3–61.6 −4.9* (−5.4, −4.4) −4.2* (−4.8, −3.6) 2015–2020 61.6–51.8 −2.6* (−4.5, −0.8) 35–64 2005–2011 125.4–83.0 −6.5* (−7.5, −5.5) −5.8* (−6.8, −4.7) 2011–2018 83.0–67.8 −3.0* (−4.2, −1.9) 2018–2020 67.8–50.4 −12.7* (−19.4, −5.3) ≥ 65 2005–2011 280.6–166.3 −7.3* (−9.9, −4.5) −6.4* (−9.2, −3.5) 2011–2020 166.3–101.4 −4.9* (−6.5, −3.2) Rural or urban Rural 2005–2010 100.9–75.3 −6.1* (−7.4, −4.9) −4.5* (−5.5, −3.5) 2010–2018 75.3–71.8 −2.1* (−3.1, −1.2) 2018–2020 71.8–56.3 −9.6* (−16.7, −1.9) Urban 2005–2008 117.3–100.1 −4.9* (−8.3, −1.4) −6.3* (−7.7, −4.9) 2008−2011 100.1−74.2 −10.8* (−17.5, −3.6) 2011−2020 74.2−44.8 −5.3* (−6.0, −4.5) Region Central China 2005−2010 122.9−84.4 −7.4* (−9.2, −5.5) −5.2* (−6, −4.5) 2010−2020 84.4−57.4 −4.1* (−4.9, −3.3) East China 2005−2011 86.5−54.5 −8.2* (−9.1, −7.3) −6.1* (−6.5, −5.6) 2011−2020 54.5−36.4 −4.6* (−5.3, −4) North China 2005−2008 79.6−72.0 −4.0* (−7.7, −0.1) −5.9* (−6.9, −4.8) 2008−2014 72.0−46.0 −8.0* (−9.8, −6.1) 2014−2020 46.0−32.6 −4.6* (−6.3, −2.9) Northeast 2005−2018 89.3−53.0 −4.6* (−5, −4.3) −6.2* (−7.3, −5.1) 2018−2020 53.0−37.4 −15.8* (−23.4, −7.4) Northwest 2005−2014 124.7−90.3 −6.3* (−8, −4.6) −6.4* (−10, −2.7) 2014−2018 90.3−113.2 5.2 (−5.5,17) 2018−2020 113.2−58.7 −26.4* (−42.9, −5.1) South China 2005−2020 136.3−60.3 −5.9* (−6.5, −5.3) −5.9* (−6.5, −5.3) Southwest 2005−2011 132.6−93.4 −6.6* (−8.6, −4.7) −4.5* (−5.5, −3.5) 2011−2020 93.4−70.1 −3.0* (−4.3, −1.8) Note. #Per 100,000 people notified in the first and last years of the segment. *Indicates that APCs (annual percentage change) and AAPCs (average annual percentage change) are significantly different from 0 at an alpha level of 0.05. PTB: pulmonary tuberculosis. -
The ASR of males was perennially higher than that of females, with an average of 104.6 (/100,000) and 48.8 (/100,000), respectively (Figure 2B). From 2005 to 2020, the average annual percentage change for males and females decreased by 6.0% and 4.9%, respectively. In 2005, the ASR of males was 159.8 (/100,000), and that of females was 72.0 (/100,000). In 2020, the ASR of males was 62.2 (/100,000), and that of females was 32.3 (/100,000). The decline for males narrowed between 2013 and 2018, with the maximum downtrend between 2018 and 2020 (APC = −10.6, 95% CI: −18.8 to −1.5). The decline for females was the largest between 2005 and 2011 (APC = −6.5, 95% CI: −7.8 to −5.3).
Among the different age groups, the average notification rate was the highest among older adults (65 years and older) (182.3/100,000), followed by middle-aged (35–64 years) (84.1/100,000), young people (15–34 years) (73.3/100,000), and children with the lowest (0–14 years) (4.8/100,000). From 2005 to 2020, the different age groups showed a downward trend, but the changes were noticeable (Table 1, Figure 2C, and Supplementary Figure S2, available in www.besjournal.com). The percentage change for children declined by 7.3% annually, with the most significant decline between 2005 and 2010 (APC = −17.4, 95% CI: −18.6 to −16.1) and a smaller decline from 2010 to 2014. However, it increased significantly by 3.3% between 2014 and 2020 (95% CI: 1.4 to 5.2). For young people, the average annual decline was 4.2%, with the smallest decline between 2015 and 2020 (APC = −2.6, 95% CI: −4.5 to −0.8). For middle-aged adults, the average annual decline was 5.8%, with the smallest decline between 2011 and 2018 and the largest decline between 2018 and 2020 (APC = −12.7, 95% CI: −19.4 to −5.3). For older adults, the average annual decline was 6.4%, with the smallest decline between 2011 and 2020 (APC = −4.9, 95% CI: −6.5 to −3.2).
-
The average ASR in rural areas (81.3 per 100,000) is higher than that in urban areas (76.1 per 100,000). From 2005 to 2010, the ASR in urban areas was slightly higher than that in rural areas. After 2011, it was continuously higher in rural areas than in urban areas (Figure 2D). From 2005 to 2020, the ASR in urban and rural areas continued to decline, with average annual decreases of 6.3% and 4.5%, respectively. In urban areas, the decline was the largest from 2008 to 2011 (APC = −10.8, 95% CI: −17.5 to −3.6) and smaller after 2011. In rural areas, the decline was the smallest from 2010 to 2018 and the largest between 2018 and 2020 (APC = −9.6, 95% CI: −16.7 to −1.9).
The average ASRs of the seven geographical regions ranged from high to low, as follows: South (103.2/100,000), Northwest (100.1/100,000), Southwest (95.3/100,000), Central (85.9/100,000), Northeast (67.4/100,000), East (57.9/100,000), and North China (56.5/100,000). South, Northwest, and Southwest China were perennially higher, while the East and North China were perennially the lowest (Figure 2E). From 2005 to 2020, all seven regions showed a downward trend with distinct changes during different periods (Table 1). The northwestern region had the maximum overall decline (AAPC = −6.4, 95% CI: −10.0 to −2.7), with a 26.4% decline from 2018 to 2020. The average annual fall was 6.2% (95% CI: −7.3 to −5.1) in the northeast region, with a maximum decline from 2018 to 2020. In East China, the average annual fall rate was 6.1% (95% CI: −6.5 to −5.6), with the most significant decline from 2005 to 2011. In North China, the average annual decline was 5.9% (95% CI: −6.9 to −4.8), with a maximum decline between 2008 and 2014. In South and Central China, the average annual decline was 5.9% (95% CI: −6.8 to −5.3) and 5.2% (95% CI: −6.0 to −4.5), respectively. The lowest annual decline was in the southwest (AAPC = −4.5, 95% CI: −5.5 to −3.5), dropping only 3.0% between 2011 and 2020.
doi: 10.3967/bes2023.015
-
Abstract:
Objective To evaluate the trend of notified incidence of pulmonary tuberculosis (PTB) in China at different periods by population and region and to explore the effect of TB prevention and control in recent years. Methods Using pooled data on TB cases reported by the TB Information Management Reporting System (TBIMS) from 2005 to 2020, we calculated the annual percentage change (APC) using the Joinpoint regression model. Results From 2005 to 2020, a total of 16.2 million cases of PTB were reported in China, with an average notified incidence of 75.5 per 100,000 population. The age standardization rate (ASR) continued to decline from 116.9 (/100,000) in 2005 to 47.6 (/100,000) in 2020, with an average annual decrease of 5.6% [APC = −5.6, 95% confidence interval (CI): −7.0 to −4.2]. The smallest decline occurred in 2011–2018 (APC = −3.4, 95% CI: −4.6 to −2.3) and the largest decrease in 2018–2020 (APC = −9.2, 95% CI: −16.4 to −1.3). From 2005 to 2020, the ASR in males (159.8 per 100,000 in 2005, 72.0 per 100,000 in 2020) was higher than that in females (62.2 per 100,000 in 2005, 32.3 per 100,000 in 2020), with an average annual decline of 6.0% for male and 4.9% for female. The average notified incidence was the highest among older adults (65 years and over) (182.3/100,000), with an average annual decline of 6.4%; children (0–14 years) were the lowest (4.8/100,000), with an average annual decline of 7.3%, but a significant increase of 3.3% between 2014 and 2020 (APC = 3.3, 95% CI: 1.4 to 5.2); middle-aged (35–64 years) decreased by 5.8%; and youth (15–34 years) decreased by an average annual rate of 4.2%. The average ASR in rural areas (81.3/100,000) is higher than that in urban areas (76.1/100,000). The average annual decline in rural areas was 4.5% and 6.3% in urban areas. South China had the highest average ASR (103.2/100,000), with an average annual decline of 5.9%, while North China had the lowest (56.5/100,000), with an average annual decline of 5.9%. The average ASR in the southwest was 95.3 (/100,000), with the smallest annual decline (APC = −4.5, 95% CI: −5.5 to −3.5); the average ASR in the Northwest China was 100.1 (/100,000), with the largest annual decline (APC = −6.4, 95% CI: −10.0 to −2.7); Central, Northeastern, and Eastern China declined by an average of 5.2%, 6.2%, and 6.1% per year, respectively. Conclusions From 2005 to 2020, the notified incidence of PTB in China continued to decline, falling by 55%. For high-risk groups such as males, older adults, high-burden areas in South, Southwest, and Northwest China, and rural regions, proactive screening should be strengthened to provide timely and effective anti-TB treatment and patient management services for confirmed cases. There is also a necessity to be vigilant about the upward trend of children in recent years, the specific reasons for which need to be further studied. -
Key words:
- Tuberculosis /
- Notified incidence /
- Joinpoint regression model /
- Trends /
- China
The authors declare that they have no conflict of interest.
Not applicable.
注释:1) AUTHOR CONTRIBUTIONS: 2) CONFLICT OF INTEREST: 3) ETHICS APPROVAL AND CONSENT TO PARTICIPATE: -
Table 1. Joinpoint regression analysis results of notified incidence of PTB in China
Characteristics Year Notification rates of PTB cases# Annual percent change (95% CI) AAPC (95% CI) Overall 2005–2008 108.3–94.6 −5.1* (−7.9, −2.2) −5.6* (−7.0, −4.2) 2008–2011 94.6–75.6 −8.6* (−14.5, −2.4) 2011–2018 75.6–61.6 −3.4* (−4.6, −2.3) 2018–2020 61.6–49.2 −9.2* (−16.4, −1.3) Sex Female 2005–2011 67.7–46.7 −6.5* (−7.8, −5.3) −4.9* (−5.5, −4.2) 2011–2020 46.7–31.8 −3.7* (−4.6, −2.9) Male 2005–2013 146.6–93.9 −6.7* (−7.5, −5.9) −6.0* (−7.3, −4.7) 2013–2018 93.9–82.9 −3.0* (−5.5, −0.3) 2018–2020 82.9–65.9 −10.6* (−18.8, −1.5) Age group 0–14 2005–2010 10.8–3.9 −17.4* (−18.6, −16.1) −7.3* (−8.6, −6.0) 2010–2014 3.9–3.0 −9.1* (−13.8, −4.0) 2014–2020 3.0–3.5 3.3* (1.4, 5.2) 15–34 2005–2015 101.3–61.6 −4.9* (−5.4, −4.4) −4.2* (−4.8, −3.6) 2015–2020 61.6–51.8 −2.6* (−4.5, −0.8) 35–64 2005–2011 125.4–83.0 −6.5* (−7.5, −5.5) −5.8* (−6.8, −4.7) 2011–2018 83.0–67.8 −3.0* (−4.2, −1.9) 2018–2020 67.8–50.4 −12.7* (−19.4, −5.3) ≥ 65 2005–2011 280.6–166.3 −7.3* (−9.9, −4.5) −6.4* (−9.2, −3.5) 2011–2020 166.3–101.4 −4.9* (−6.5, −3.2) Rural or urban Rural 2005–2010 100.9–75.3 −6.1* (−7.4, −4.9) −4.5* (−5.5, −3.5) 2010–2018 75.3–71.8 −2.1* (−3.1, −1.2) 2018–2020 71.8–56.3 −9.6* (−16.7, −1.9) Urban 2005–2008 117.3–100.1 −4.9* (−8.3, −1.4) −6.3* (−7.7, −4.9) 2008−2011 100.1−74.2 −10.8* (−17.5, −3.6) 2011−2020 74.2−44.8 −5.3* (−6.0, −4.5) Region Central China 2005−2010 122.9−84.4 −7.4* (−9.2, −5.5) −5.2* (−6, −4.5) 2010−2020 84.4−57.4 −4.1* (−4.9, −3.3) East China 2005−2011 86.5−54.5 −8.2* (−9.1, −7.3) −6.1* (−6.5, −5.6) 2011−2020 54.5−36.4 −4.6* (−5.3, −4) North China 2005−2008 79.6−72.0 −4.0* (−7.7, −0.1) −5.9* (−6.9, −4.8) 2008−2014 72.0−46.0 −8.0* (−9.8, −6.1) 2014−2020 46.0−32.6 −4.6* (−6.3, −2.9) Northeast 2005−2018 89.3−53.0 −4.6* (−5, −4.3) −6.2* (−7.3, −5.1) 2018−2020 53.0−37.4 −15.8* (−23.4, −7.4) Northwest 2005−2014 124.7−90.3 −6.3* (−8, −4.6) −6.4* (−10, −2.7) 2014−2018 90.3−113.2 5.2 (−5.5,17) 2018−2020 113.2−58.7 −26.4* (−42.9, −5.1) South China 2005−2020 136.3−60.3 −5.9* (−6.5, −5.3) −5.9* (−6.5, −5.3) Southwest 2005−2011 132.6−93.4 −6.6* (−8.6, −4.7) −4.5* (−5.5, −3.5) 2011−2020 93.4−70.1 −3.0* (−4.3, −1.8) Note. #Per 100,000 people notified in the first and last years of the segment. *Indicates that APCs (annual percentage change) and AAPCs (average annual percentage change) are significantly different from 0 at an alpha level of 0.05. PTB: pulmonary tuberculosis. -
[1] To KW, Reino JJ, Yoo DH, et al. Tumour necrosis factor antagonist and tuberculosis in patients with rheumatoid arthritis: an Asian perspective. Respirology, 2013; 18, 765−73. doi: 10.1111/resp.12106 [2] Wang LX, Zhang H, Ruan YZ, et al. Tuberculosis prevalence in China, 1990–2010; a longitudinal analysis of national survey data. Lancet, 2014; 383, 2057−64. doi: 10.1016/S0140-6736(13)62639-2 [3] Zhang H, Liu JJ, Du X. Data analysis of new smear-positive pulmonary tuberculosis patients in China in 2005. Chin J Antituberc, 2008; 107−9. (In Chinese [4] WHO. Global tuberculosis report 2021. Licence: CC BY-NC-SA 3.0 IGO. , 2021. [5] Wang YS, Zhu WL, Li T, et al. Changes in newly notified cases and control of tuberculosis in China: time-series analysis of surveillance data. Infect Dis Poverty, 2021; 10, 16. doi: 10.1186/s40249-021-00806-7 [6] Dong Z, Wang QQ, Yu SC, et al. Application of disability-adjusted life years to evaluate the burden and trend of tuberculosis—China, 1990–2019. China CDC Wkly, 2022; 4, 220−5. [7] Floyd K, Glaziou P, Houben RMGJ, et al. Global tuberculosis targets and milestones set for 2016-2035: definition and rationale. Int J Tuberc Lung Dis, 2018; 22, 723−30. doi: 10.5588/ijtld.17.0835 [8] Marvi A, Asadi-Aliabadi M, Darabi M, et al. Silent changes of tuberculosis in Iran (2005–2015): a joinpoint regression analysis. J Family Med Prim Care, 2017; 6, 760−5. doi: 10.4103/jfmpc.jfmpc_190_17 [9] Essien SK, Epp T, Waldner C, et al. Tuberculosis in Canada and the United States: a review of trends from 1953 to 2015. Can J Public Health, 2019; 110, 697−704. doi: 10.17269/s41997-019-00236-x [10] Dhamnetiya D, Patel P, Jha RP, et al. Trends in incidence and mortality of tuberculosis in India over past three decades: a joinpoint and age–period–cohort analysis. BMC Pulm Med, 2021; 21, 375. doi: 10.1186/s12890-021-01740-y [11] Van Doren TP, Sattenspiel L. The 1918 influenza pandemic did not accelerate tuberculosis mortality decline in early‐20th century Newfoundland: investigating historical and social explanations. Am J Phys Anthropol, 2021; 176, 179−91. doi: 10.1002/ajpa.24332 [12] Zuo ZB, Wang MC, Cui HZ, et al. Spatiotemporal characteristics and the epidemiology of tuberculosis in China from 2004 to 2017 by the nationwide surveillance system. BMC Public Health, 2020; 20, 1284. doi: 10.1186/s12889-020-09331-y [13] Bureau of Disease Control and Prevention, Ministry of Health. Guidelines for implementation of tuberculosis prevention and control program in China 2008 edition. China Union Medical College Press, 2009. (In Chinese) [14] Yao S, Fang XH. Interpretation and consideration of 2020 edition technical specifications for TB prevention and control in China. J Trop Dis Parasitol, 2020; 18, 138−41, 137. (In Chinese [15] National Health Commission of the PRC. Technical specifications for tuberculosis prevention and control in China (2020). Technical specifications for tuberculosis prevention and control in China, 2020 edition. 2020. (In Chinese) [16] Lu W, Zhou Y, Liu JJ. The Progress and achievements of tuberculosis control in China since 1949. Chin J Dis Control Prev, 2019; 23, 754−7, 62. (In Chinese [17] Bloom G, Gu XY. Health sector reform: lessons from China. Soc Sci Med, 1997; 45, 351−60. doi: 10.1016/S0277-9536(96)00350-4 [18] Liu JJ. Progress of tuberculosis control program in China. Chinese Medical Association, 2004; 5−9. (In Chinese [19] Zhao YJ, Wang SY. Promoting the prevention and control strategy of tuberculosis scientifically to achieve "the 13th Five-year Plan" for tuberculosis control program. Chin J Dis Control Prev, 2017; 21, 431−3, 538. (In Chinese [20] General Office of the State Council of the People's Republic of China. National tuberculosis control plan (2011-2015). Chin Pract J Rural Doct, 2012; 19, 1−3. (In Chinese [21] Huang F, Cheng SM, Du X, et al. Electronic recording and reporting system for tuberculosis in China: experience and opportunities. J Am Med Inform Assoc, 2014; 21, 938−41. doi: 10.1136/amiajnl-2013-002001 [22] Census Office of the State Council. China's 2010 census. China Statistics Press. 2012. (In Chinese) [23] Zhao CF, Gao F, Li QW, et al. The distributional characteristic and growing trend of pancreatic cancer in China. Pancreas, 2019; 48, 309−14. doi: 10.1097/MPA.0000000000001222 [24] Kim HJ, Luo J, Kim J, et al. Clustering of trend data using joinpoint regression models. Stat Med, 2014; 33, 4087−103. doi: 10.1002/sim.6221 [25] Cui YR, Shen H, Wang F, et al. A long-term trend study of tuberculosis incidence in China, India and United States 1992–2017: a joinpoint and age–period–cohort analysis. Int J Environ Res Public Health, 2020; 17, 3334. doi: 10.3390/ijerph17093334 [26] Wang LQ, Wang WB. Temporal trends in notification and mortality of tuberculosis in China, 2004-2019: a joinpoint and age-period-cohort analysis. Int J Environ Res Public Health, 2021; 18, 5607. doi: 10.3390/ijerph18115607 [27] WHO. National tuberculosis prevalence surveys 2007-2016. WHO. 2021. [28] Liu SY, Bi YJ, Liu YW. Modeling and dynamic analysis of tuberculosis in mainland China from 1998 to 2017: the effect of DOTS strategy and further control. Theor Biol Med Model, 2020; 17, 6. doi: 10.1186/s12976-020-00124-9 [29] Wang L, Cheng S, Xu M, et al. Model collaboration between hospitals and public health system to improve tuberculosis control in China. Int J Tuberc Lung Dis, 2009; 13, 1486−92. [30] Jiang SW, Zhang H, Wang DM, et al. Contribution of the Global Fund's Tuberculosis program to Tuberculosis control in China. Chin J Antituberc, 2014; 36, 305−7. (In Chinese [31] Schwartz NG, Price SF, Pratt RH, et al. Tuberculosis—United States, 2019. MMWR Morb Mortal Wkly Rep, 2020; 69, 286−9. doi: 10.15585/mmwr.mm6911a3 [32] Ren TT, Lu PX, Deng GF, et al. 2020 WHO tuberculosis report: key data for China and the whole world. Electron J Emerg Infect Dis, 2020; 5, 280−4. (In Chinese [33] Ma Y, Lu W, Gao L, et al. To end tuberculosis epidemic needs strengthen the management of screening and preventive treatment of latent tuberculosis infection in high-risk groups. Chin J Antituberc, 2022; 44, 209−14. (In Chinese [34] Xu CH, Zhang XM, Liu Y, et al. Factors associated with diagnostic delay of pulmonary tuberculosis in China. Biomed Environ Sci, 2022; 35, 73−8. [35] Li T, Sun YN, Zhang H, et al. Experience and implications of the 2011 Global Fund on international project management. Chin Prev Med, 2015; 16, 728−30. (In Chinese [36] Deutsch-Feldman M, Pratt RH, Price SF, et al. Tuberculosis—United States, 2020. MMWR Morb Mortal Wkly Rep, 2021; 70, 409−14. doi: 10.15585/mmwr.mm7012a1 [37] Kwak N, Hwang SS, Yim JJ. Effect of COVID-19 on tuberculosis notification, South Korea. Emerg Infect Dis, 2020; 26, 2506−8. doi: 10.3201/eid2610.202782 [38] Geng YM, Li G, Zhang LL. The impact of COVID-19 Interventions on influenza and Mycobacterium tuberculosis infection. Front Public Health, 2021; 9, 672568. doi: 10.3389/fpubh.2021.672568 [39] Huang F, Xia YY, Chen H, et al. The impact of the COVID-19 epidemic on tuberculosis control in China. Lancet Reg Health West Pac, 2020; 3, 100032. doi: 10.1016/j.lanwpc.2020.100032 [40] Cheng J, Sun YN, Zhang CY, et al. Incidence and risk factors of tuberculosis among the elderly population in China: a prospective cohort study. Infect Dis Poverty, 2020; 9, 13. doi: 10.1186/s40249-019-0614-9 [41] Mori T, Leung CC. Tuberculosis in the global aging population. Infect Dis Clin North Am, 2010; 24, 751−68. doi: 10.1016/j.idc.2010.04.011 [42] Yang RL, Liu MY, Jiang H, et al. The epidemiology of pulmonary tuberculosis in children in Mainland China, 2009–2015. Arch Dis Child, 2020; 105, 319−25. doi: 10.1136/archdischild-2019-317635 [43] Wang YH, Tian Y, Gao JX, et al. Tuberculosis prevalence among university freshmen in Zhengzhou, China, during 2004-2013. Afr Health Sci, 2018; 18, 1109−16. doi: 10.4314/ahs.v18i4.32 [44] Yang S, Gao Y, Luo W, et al. Spatiotemporal distribution of tuberculosis during urbanization in the new urban area of Nanchang City, China, 2010–2018. Int J Environ Res Public Health, 2019; 16, 4395. doi: 10.3390/ijerph16224395 [45] Alirol E, Getaz L, Stoll B, et al. Urbanisation and infectious diseases in a globalised world. The Lancet Infect Dis, 2011; 11, 131−41. doi: 10.1016/s1473-3099(10)70223-1 [46] Yan F, Thomson R, Tang SL, et al. Multiple perspectives on diagnosis delay for tuberculosis from key stakeholders in poor rural China: case study in four provinces. Health Policy, 2007; 82, 186−99. doi: 10.1016/j.healthpol.2006.08.001 [47] Tao NN, He XC, Zhang XX, et al. Trends and characteristics of drug-resistant tuberculosis in rural Shandong, China. Int J Infect Dis, 2017; 65, 8−14. doi: 10.1016/j.ijid.2017.09.019 [48] Li HM, Cheng B, Chen YC. What causes high costs for rural tuberculosis inpatients? Evidence from five counties in China. BMC Infect Dis, 2020; 20, 501. doi: 10.1186/s12879-020-05235-9 [49] Li Q, Jiang WX, Wang QL, et al. Non-medical financial burden in tuberculosis care: a cross-sectional survey in rural China. Infect Dis Poverty, 2016; 5, 5. doi: 10.1186/s40249-016-0101-5 [50] Shang Y, Zhang TT, Wang ZF, et al. Spatial epidemiological characteristics and Exponential smoothing model application of Tuberculosis in Qinghai Plateau, China. Epidemiol Infect, 2022; 150, e37. doi: 10.1017/S0950268822000036 [51] Li JZ, Li YH, Ye M, et al. Forecasting the tuberculosis incidence using a novel ensemble empirical mode decomposition-based data-driven hybrid model in Tibet, China. Infect Drug Resist, 2021; 14, 1941−55. doi: 10.2147/IDR.S299704 [52] He XY, Cao MQ, Mahapatra T, et al. Burden of tuberculosis in Xinjiang between 2011 and 2015: a surveillance data-based study. PLoS One, 2017; 12, e0187592. doi: 10.1371/journal.pone.0187592 [53] Mijiti P, Li YH, Feng X, et al. Prevalence of pulmonary tuberculosis in western China in 2010–11: a population-based, cross-sectional survey. Lancet Glob Health, 2016; 4, e485−94. doi: 10.1016/S2214-109X(16)30074-2 [54] Zhang JJ, Yang YY, Qiao X, et al. Factors influencing medication nonadherence to pulmonary tuberculosis treatment in Tibet, China: a qualitative study from the patient perspective. Patient Prefer Adherence, 2020; 14, 1149−58. doi: 10.2147/PPA.S252448 [55] Liu CF, Song YM, He P, et al. Evaluation of multidrug resistant loop-mediated isothermal amplification assay for detecting the drug resistance of Mycobacterium tuberculosis. Biomed Environ Sci, 2021; 34, 616−22. -
22158Supplementary Materials.pdf